Inactivation of the tumor suppressor genes causing the hereditary syndromes predisposing to head and neck cancer via promoter hypermethylation in sporadic head and neck cancers

ORL

Volumn 72, Issue 1, 2010, Pages 44-50

  Smith, Ian M ^a   Mithani, Suhail K ^b   Mydlarz, Wojciech K ^a   Chang, Steven S ^a   Califano, Joseph A ^a,b,c  

^a Head and Neck Cancer Division   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

^c GREATER BALTIMORE MEDICAL CENTER   (United States)

Author keywords

Dyskeratosis congenita; Fanconi anemia; Head and neck cancer; Hypermethylation; Leukoplakia

Indexed keywords

BISULFITE;

ADULT; AGED; ARTICLE; ATM GENE; BACH1 GENE; BRCA2 GENE; BRIP1 GENE; CLINICAL ARTICLE; CONTROLLED STUDY; DKC1 GENE; DNA METHYLATION; DYSKERATOSIS CONGENITA; FANCA GENE; FANCB GENE; FANCC GENE; FANCD1 GENE; FANCD2 GENE; FANCE GENE; FANCF GENE; FANCG GENE; FANCJ GENE; FANCL GENE; FANCM GENE; FANCONI ANEMIA; FEMALE; GENE SILENCING; HEAD AND NECK CANCER; HEF GENE; HUMAN; HUMAN TISSUE; MALE; NBS1 GENE; PHF9 GENE; POG GENE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RAD51 GENE; SQUAMOUS CELL CARCINOMA; TERC GENE; TUMOR SUPPRESSOR GENE; XRCC9 GENE;

BASIC-LEUCINE ZIPPER TRANSCRIPTION FACTORS; BIOPSY; CARCINOMA, SQUAMOUS CELL; CELL CYCLE PROTEINS; CHI-SQUARE DISTRIBUTION; DNA METHYLATION; DYSKERATOSIS CONGENITA; EPIGENESIS, GENETIC; FANCONI ANEMIA; FANCONI ANEMIA COMPLEMENTATION GROUP PROTEINS; GENE SILENCING; GENES, TUMOR SUPPRESSOR; GENETIC PREDISPOSITION TO DISEASE; HEAD AND NECK NEOPLASMS; HUMANS; NUCLEAR PROTEINS; POLYMERASE CHAIN REACTION; PROMOTER REGIONS, GENETIC;

EID: 77949545721     PISSN: 03011569     EISSN: None     Source Type: Journal    
DOI: 10.1159/000292104     Document Type: Article

References (44)

1. Kim MM, Califano JA: Molecular pathology of head-and-neck cancer. Int J Cancer 2004; 112: 545-553.
2. Califano J, van der Riet P, Westra W, Nawroz H, Clayman G, Piantadosi S, Corio R, Lee D, Greenberg B, Koch W, Sidransky D: Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res 1996; 56: 2488-2492.
3. Li FP, Fraumeni JF Jr: Soft-tissue sarcomas, breast cancer, and other neoplasms: a familial syndrome? Ann Intern Med 1969; 71: 747-752.
4. Gardner EJ: A genetic and clinical study of intestinal polyposis, a predisposing factor for carcinoma of the colon and rectum. Am J Hum Genet 1951; 3: 167-176.
5. Kennedy AW, Hart WR: Multiple squamouscell carcinomas in Fanconi's anemia. Cancer 1982; 50: 811-814.
6. Alter BP: Cancer in Fanconi anemia 1927- 2001. Cancer 2003; 97: 425-440.
7. Collins N, Kupfer GM: Molecular pathogenesis of Fanconi anemia. Int J Hematol 2005; 82: 176-183.
8. Bagby GC Jr: Genetic basis of Fanconi anemia. Curr Opin Hematol 2003; 10: 68-76.
9. Joenje H, Patel KJ: The emerging genetic and molecular basis of Fanconi anaemia. Nat Rev Genet 2001; 2: 446-457.
10. D'Andrea AD: The Fanconi road to cancer. Genes Dev 2003; 17: 1933-1936.
11. Van Waes C: Head and neck squamous cell carcinoma in patients with Fanconi anemia. Arch Otolaryngol Head Neck Surg 2005; 131: 640-641.
12. Rosenberg PS, Greene MH, Alter BP: Cancer incidence in persons with Fanconi anemia. Blood 2003; 101: 822-826.
13. Alter BP, Joenje H, Oostra AB, Pals G: Fanconi anemia: adult head and neck cancer and hematopoietic mosaicism. Arch Otolaryngol Head Neck Surg 2005; 131: 635-639.
14. Sirinavin C, Trowbridge AA: Dyskeratosis congenita: clinical features and genetic aspects: report of a family and review of the literature. J Med Genet 1975; 12: 339-354.
15. Dokal I: Dyskeratosis congenita in all its forms. Br J Haematol 2000; 110: 768-779.
16. Walne AJ, Marrone A, Dokal I: Dyskeratosis congenita: a disorder of defective telomere maintenance? Int J Hematol 2005; 82: 184-189.
17. Vulliamy TJ, Marrone A, Knight SW, Walne A, Mason PJ, Dokal I: Mutations in dyskeratosis congenita: their impact on telomere length and the diversity of clinical presentation. Blood 2006; 107: 2680-2685.
18. Yoon A, Peng G, Brandenburger Y, Zollo O, Xu W, Rego E, Ruggero D: Impaired control of IRES-mediated translation in X-linked dyskeratosis congenita. Science 2006; 312: 902-906.
19. Loukinov DI, Pugacheva E, Vatolin S, Pack SD, Moon H, Chernukhin I, Mannan P, Larsson E, Kanduri C, Vostrov AA, Cui H, Niemitz EL, Rasko JE, Docquier FM, Kistler M, Breen JJ, Zhuang Z, Quitschke WW, Renkawitz R, Klenova EM, Feinberg AP, Ohlsson R, Morse HC 3rd, Lobanenkov VV: BORIS, a novel male germ-line-specific protein associated with epigenetic reprogramming events, shares the same 11-zinc-finger domain with CTCF, the insulator protein involved in reading imprinting marks in the soma. Proc Natl Acad Sci USA 2002; 99: 6806-6811.
20. Wald C, Diner H: Dyskeratosis congenita with associated periodontal disease. Oral Surg Oral Med Oral Pathol 1974; 37: 736-744.
21. Treister N, Lehmann LE, Cherrick I, Guinan EC, Woo SB: Dyskeratosis congenita vs. chronic graft versus host disease: report of a case and a review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2004; 98: 566-571.
22. Knight S, Vulliamy T, Copplestone A, Gluckman E, Mason P, Dokal I: Dyskeratosis Congenita (DC) Registry: identification of new features of DC. Br J Haematol 1998; 103: 990-996.
23. Addison M, Rice MS: The association of dyskeratosis congenita and Fanconi's Anaemia. Med J Aust 1965; 18: 797-799.
24. Anil S, Beena VT, Raji MA, Remani P, Ankathil R, Vijayakumar T: Oral squamous cell carcinoma in a case of dyskeratosis congenita. Ann Dent 1994; 53: 15-18.
25. Benoit S, Kraemer D, Brocker EB, Goebeler M: Dyskeratosis congenita in a 40-year-old patient (in German). Hautarzt 2006; 57: 313-316.
26. Cannell H: Dyskeratosis congenita. Br J Oral Surg 1971; 9: 8-20.
27. Cole HN, Rauschkolb J, Toomey J: Dyskeratosis congenita with pigmentation, dystrophia unguium, and leucokeratosis oris: review of the known cases reported to date and discussion of the disease from various aspects. AMA Arch Derm 1955; 71: 451-456.
28. Garb J: Dyskeratosis congenita with pigmentation, dystrophia unguium, and leukoplakia oris; a follow-up report of two brothers. AMA Arch Derm 1958; 77: 704-712.
29. Hyodo M, Sadamoto A, Hinohira Y, Yumoto E: Tongue cancer as a complication of dyskeratosis congenita in a woman. Am J Otolaryngol 1999; 20: 405-407.
30. Llistosella E, Moreno A, de Moragas JM: Dyskeratosis congenita with macular cutaneous amyloid deposits. Arch Dermatol 1984; 120: 1381-1382.
31. Moretti S, Spallanzani A, Chiarugi A, Muscarella G, Battini ML: Oral carcinoma in a young man: a case of dyskeratosis congenita. J Eur Acad Dermatol Venereol 2000; 14: 123-125.
32. Dong SM, Sun DI, Benoit NE, Kuzmin I, Lerman MI, Sidransky D: Epigenetic inactivation of RASSF1A in head and neck cancer. Clin Cancer Res 2003; 9: 3635-3640. (Pubitemid 37169228)
33. Sanchez-Cespedes M, Esteller M, Wu L, Nawroz-Danish H, Yoo GH, Koch WM, Jen J, Herman JG, Sidransky D: Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. Cancer Res 2000; 60: 892-895.
34. Reed AL, Califano J, Cairns P, Westra WH, Jones RM, Koch W, Ahrendt S, Eby Y, Sewell D, Nawroz H, Bartek J, Sidransky D: High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res 1996; 56: 3630-3633.
35. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB, Sidransky D: 5 CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1995; 1: 686-692.
36. Herman JG, Merlo A, Mao L, Lapidus RG, Issa JP, Davidson NE, Sidransky D, Baylin SB: Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 1995; 55: 4525-4530.
37. Ha PK, Califano JA: Promoter methylation and inactivation of tumour-suppressor genes in oral squamous-cell carcinoma. Lancet Oncol 2006; 7: 77-82.
38. Jones PA, Takai D: The role of DNA methylation in mammalian epigenetics. Science 2001; 293: 1068-1070.
39. D'Andrea AD: The Fanconi anemia/BRCA signaling pathway: disruption in cisplatinsensitive ovarian cancers. Cell Cycle 2003; 2: 290-292.
40. Narayan G, Arias-Pulido H, Nandula SV, Basso K, Sugirtharaj DD, Vargas H, Mansukhani M, Villella J, Meyer L, Schneider A, Gissmann L, Durst M, Pothuri B, Murty VV: Promoter hypermethylation of FANCF: disruption of Fanconi anemia-BRCA pathway in cervical cancer. Cancer Res 2004; 64: 2994-2997.
41. Marsit CJ, Liu M, Nelson HH, Posner M, Suzuki M, Kelsey KT: Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival. Oncogene 2004; 23: 1000-1004.
42. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB: Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996; 93: 9821-9826.
43. Harden SV, Tokumaru Y, Westra WH, Goodman S, Ahrendt SA, Yang SC, Sidransky D: Gene promoter hypermethylation in tumors and lymph nodes of stage I lung cancer patients. Clin Cancer Res 2003; 9: 1370-1375.
44. Sparano A, Quesnelle KM, Kumar MS, Wang Y, Sylvester AJ, Feldman M, Sewell DA, Weinstein GS, Brose MS: Genome-wide profiling of oral squamous cell carcinoma by array-based comparative genomic hybridization. Laryngoscope 2006; 116: 735-741.